Trevor Phinney, DO
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Bayer at 58.9% of the total. 2025 is the largest year on record at $7,351, more than ten times the $543 reported in 2019.
Across 135 payments — averaging $117.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$9K
- E.r. Squibb & Sons, L.L.C.$4K
- Johnson & Johnson$2K
- Janssen Research & Development, LLC$539
- Teva Pharmaceuticals USA, Inc.$210
- Lilly USA, LLC$124
- plus $139 from 3 others
Across 41 payments — averaging $22,903 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$734K
- Bayer$138K
- Janssen Research & Development, LLC$67K
What the payments were for
- Consulting fees$8,94857%
- Travel & lodging$3,19920%
- Food & beverage$3,65823%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 27 | $9,301 |
| E.r. Squibb & Sons, L.L.C. | 1 | $3,675 |
| Johnson & Johnson | 92 | $1,815 |
| Janssen Research & Development, LLC | 6 | $539 |
| Teva Pharmaceuticals USA, Inc. | 2 | $210 |
| Lilly USA, LLC | 3 | $124 |
| UCB, Inc. | 1 | $85 |
| Janssen Scientific Affairs, LLC | 2 | $38 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,804 in reported general payments places this provider in the 80th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 13 | $78 |
| Pantoprazole Sodium | 15 | $4 |
Paid to pharmacies, not to this prescriber.
Other neurology in Erie
- Daniel KremensPhiladelphia$1.8M
- Thomas LeistPhiladelphia$1.4M
- Jill Giordano FarmerPhiladelphia$1.2M
- Ravi DukkipatiYork$936K
- Brad KleinAbington$927K
- Stephanie Nahas-GeigerPhiladelphia$786K
- John KhouryAbington$686K
- Amit Bar-OrPhiladelphia$596K
- Behrang SaminejadAllentown$594K
- Anoopum GuptaPittsburgh$592K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.